Alan K. Burnett

4.6k total citations
35 papers, 2.3k citations indexed

About

Alan K. Burnett is a scholar working on Hematology, Molecular Biology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Alan K. Burnett has authored 35 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Hematology, 15 papers in Molecular Biology and 11 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Alan K. Burnett's work include Acute Myeloid Leukemia Research (21 papers), Acute Lymphoblastic Leukemia research (11 papers) and Chronic Lymphocytic Leukemia Research (6 papers). Alan K. Burnett is often cited by papers focused on Acute Myeloid Leukemia Research (21 papers), Acute Lymphoblastic Leukemia research (11 papers) and Chronic Lymphocytic Leukemia Research (6 papers). Alan K. Burnett collaborates with scholars based in United Kingdom, Belgium and United States. Alan K. Burnett's co-authors include Robert K. Hills, Keith Wheatley, David C. Linch, Rosemary E. Gale, Anthony H. Goldstone, Richard L. Darley, Alastair G. Smith, Richard E. Clark, Alex Tonks and R. M. Hutchinson and has published in prestigious journals such as Blood, Biochemical and Biophysical Research Communications and British Journal of Haematology.

In The Last Decade

Alan K. Burnett

35 papers receiving 2.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Alan K. Burnett United Kingdom	23	1.7k	1.0k	533	501	399	35	2.3k
Sören Lehmann Sweden	27	1.2k 0.7×	1.2k 1.2×	363 0.7×	507 1.0×	667 1.7×	77	2.3k
Steven Knapper United Kingdom	23	1.7k 1.0×	1.2k 1.1×	323 0.6×	825 1.6×	286 0.7×	91	2.4k
Maximilian Stahl United States	25	1.3k 0.7×	970 0.9×	236 0.4×	387 0.8×	466 1.2×	121	2.0k
Jay P. Patel United States	11	1.1k 0.6×	993 1.0×	247 0.5×	487 1.0×	175 0.4×	23	1.8k
Stephen A. Strickland United States	27	1.8k 1.0×	1.4k 1.3×	383 0.7×	460 0.9×	503 1.3×	99	2.4k
Brian A. Jonas United States	26	2.5k 1.4×	1.9k 1.8×	621 1.2×	691 1.4×	698 1.7×	122	3.5k
Claire Seedhouse United Kingdom	25	547 0.3×	1.1k 1.1×	307 0.6×	158 0.3×	548 1.4×	62	1.7k
Edward J. Lee United States	17	858 0.5×	421 0.4×	389 0.7×	222 0.4×	500 1.3×	27	1.6k
Ji Yuan Wu United States	21	908 0.5×	712 0.7×	104 0.2×	803 1.6×	666 1.7×	44	2.1k
Oliver Galm Germany	23	602 0.3×	1.5k 1.4×	100 0.2×	231 0.5×	436 1.1×	51	2.0k

Countries citing papers authored by Alan K. Burnett

Since Specialization

Citations

This map shows the geographic impact of Alan K. Burnett's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alan K. Burnett with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alan K. Burnett more than expected).

Fields of papers citing papers by Alan K. Burnett

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alan K. Burnett. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alan K. Burnett. The network helps show where Alan K. Burnett may publish in the future.

Co-authorship network of co-authors of Alan K. Burnett

This figure shows the co-authorship network connecting the top 25 collaborators of Alan K. Burnett. A scholar is included among the top collaborators of Alan K. Burnett based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alan K. Burnett. Alan K. Burnett is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Walter, Roland B., Megan Othus, Alan K. Burnett, et al.. (2014). Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center. Leukemia. 29(2). 312–320. 116 indexed citations

Nacheva, E, Colin Grace, Diana Brazma, et al.. (2013). Does BCR/ABL1 positive Acute Myeloid Leukaemia Exist?. British Journal of Haematology. 161(4). 541–550. 42 indexed citations

Coles, Steven, Eddie C. Y. Wang, Stephen Man, et al.. (2011). CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia. Leukemia. 25(5). 792–799. 141 indexed citations

Hills, Robert K. & Alan K. Burnett. (2011). Applicability of a “Pick a Winner” trial design to acute myeloid leukemia. Blood. 118(9). 2389–2394. 58 indexed citations

Walsby, Elisabeth, Steven Coles, Steven Knapper, & Alan K. Burnett. (2010). The topoisomerase II inhibitor voreloxin causes cell cycle arrest and apoptosis in myeloid leukemia cells and acts in synergy with cytarabine. Haematologica. 96(3). 393–399. 45 indexed citations

Burnett, Alan K., Donald Milligan, Anthony P. Goldstone, et al.. (2009). The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial. British Journal of Haematology. 145(3). 318–332. 110 indexed citations

Wheatley, Keith, Anthony H. Goldstone, Tim Littlewood, Anne Hunter, & Alan K. Burnett. (2009). Randomized placebo‐controlled trial of granulocyte colony stimulating factor (G‐CSF) as supportive care after induction chemotherapy in adult patients with acute myeloid leukaemia: a study of the United Kingdom Medical Research Council Adult Leukaemia Working Party. British Journal of Haematology. 146(1). 54–63. 27 indexed citations

Burnett, Alan K., Robert K. Hills, Claire Green, et al.. (2009). The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA. Blood. 115(5). 948–956. 83 indexed citations

Advani, Anjali S., Stephen P. Hunger, & Alan K. Burnett. (2009). Acute Leukemia in Adolescents and Young Adults. Seminars in Oncology. 36(3). 213–226. 34 indexed citations

10.

Walsby, Elisabeth, et al.. (2008). Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts. Haematologica. 93(5). 662–669. 72 indexed citations

11.

Mead, Adam J., David C. Linch, Robert K. Hills, et al.. (2007). FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia. Blood. 110(4). 1262–1270. 230 indexed citations

12.

Burnett, Alan K., Robert K. Hills, David Grimwade, et al.. (2007). Idarubicin and ATRA Is as Effective as MRC Chemotherapy in Patients with Acute Promyelocytic Leukaemia with Lower Toxicity and Resource Usage: Preliminary Results of the MRC AML15 Trial.. Blood. 110(11). 589–589. 14 indexed citations

13.

Holt, Bronno van der, Dimitri Breems, H. Berna Beverloo, et al.. (2006). Various distinctive cytogenetic abnormalities in patients with acute myeloid leukaemia aged 60 years and older express adverse prognostic value: results from a prospective clinical trial. British Journal of Haematology. 136(1). 96–105. 47 indexed citations

14.

Tonks, Alex, Alex Tonks, Amanda J. Tonks, et al.. (2005). Optimized Retroviral Transduction Protocol Which Preserves the Primitive Subpopulation of Human Hematopoietic Cells. Biotechnology Progress. 21(3). 953–958. 15 indexed citations

15.

Guinn, Barbara‐ann, Amanda Gilkes, E. L. Woodward, et al.. (2005). Microarray analysis of tumour antigen expression in presentation acute myeloid leukaemia. Biochemical and Biophysical Research Communications. 333(3). 703–713. 29 indexed citations

16.

Burnett, Alan K., Donald Milligan, Robert K. Hills, et al.. (2004). Does All-Transretinoic Acid (ATRA) Have a Role in Non-APL Acute Myeloid Leukaemia?: Results from 1666 Patients in Three MRC Trials.. Blood. 104(11). 1794–1794. 4 indexed citations

17.

Goldstone, Anthony H., Alan K. Burnett, Keith Wheatley, et al.. (2001). Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood. 98(5). 1302–1311. 336 indexed citations

18.

McGlynn, Angela Provitera, Rose Ann Padua, Alan K. Burnett, & Richard L. Darley. (2000). Alternative effects of RAS and RAF oncogenes on the proliferation and apoptosis of factor-dependent FDC-P1 cells. Leukemia Research. 24(1). 47–54. 10 indexed citations

19.

Zaker, Farhad, et al.. (1997). Oncogenic RAS genes impair erythroid differentiation of erythroleukaemia cells. Leukemia Research. 21(7). 635–640. 11 indexed citations

20.

Baines, Paul, et al.. (1995). Responsiveness to stem cell factor (SCF) of peripheral blood colony-forming cells from patients with myelodysplastic syndromes (MDS). Leukemia Research. 19(8). 561–566. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact